Nicolas Poirier, Ph.D. – OSE Immunotherapeutics – discusses Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells in Immuno-Oncology and New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI®) and Bifunctional Therapy Targeting PD-1 and IL-7 (BiCKI®-IL-7) For Cancer Immunotherapy – What is the next step for this research?
Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors and Bispecific Antibody Checkpoint Inhibitor Platform BiCKI® and BiCKI®-IL-7 -What is the next step for…
